Turning Point Therapeutics (NASDAQ:TPTX) Announces Quarterly Earnings Results
Turning Point Therapeutics (NASDAQ:TPTX) Announces Quarterly Earnings Results
Turning Point Therapeutics (NASDAQ:TPTX – Get Rating) announced its quarterly earnings data on Monday. The company reported ($2.48) earnings per share for the quarter, missing the consensus estimate of ($1.70) by ($0.78), Briefing.com reports. The business had revenue of $0.12 million during the quarter, compared to analysts' expectations of $2.27 million. During the same period in the prior year, the firm earned ($1.14) EPS. The business's revenue was down 97.7% on a year-over-year basis.
转折点治疗公司(纳斯达克:TPTX-GET评级)周一公布了季度收益数据。据Briefing.com报道,该公司公布的季度每股收益为2.48美元,低于普遍预期的1.70美元和0.78美元。该业务当季营收为12万美元,高于分析师预期的227万美元。去年同期,该公司每股收益为1.14美元。该业务的收入同比下降了97.7%。
Turning Point Therapeutics Stock Up 0.1 %
转折点治疗公司股票上涨0.1%
Turning Point Therapeutics stock opened at $75.06 on Tuesday. Turning Point Therapeutics has a one year low of $23.77 and a one year high of $82.20. The business's fifty day moving average is $72.49 and its 200 day moving average is $45.76.
周二,Turning Point Treateutics的股票开盘报75.06美元。Turning Point Treeutics的一年低点为23.77美元,一年高位为82.20美元。该业务的50日移动均线切入位为72.49美元,200日移动均线切入位为45.76美元。
Wall Street Analyst Weigh In
华尔街分析师也加入进来
Several brokerages have weighed in on TPTX. The Goldman Sachs Group lowered their price objective on Turning Point Therapeutics from $143.00 to $116.00 and set a "buy" rating for the company in a research report on Tuesday, May 24th. SVB Leerink downgraded Turning Point Therapeutics from an "outperform" rating to a "market perform" rating and decreased their target price for the company from $101.00 to $76.00 in a report on Monday, June 13th. Wells Fargo & Company downgraded Turning Point Therapeutics from an "overweight" rating to an "equal weight" rating and set a $76.00 target price for the company. in a report on Friday, June 3rd. Cowen downgraded Turning Point Therapeutics from an "outperform" rating to a "market perform" rating in a report on Monday, June 6th. Finally, Wedbush cut Turning Point Therapeutics from an "outperform" rating to a "neutral" rating and upped their price target for the stock from $61.00 to $76.00 in a research note on Friday, June 3rd. Nine research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $78.22.
几家券商已经对TPTX发表了看法。高盛夫妇将他们对Turning Point Treateutics的目标价从143.00美元下调至116.00美元,并在周二的一份研究报告中为该公司设定了“买入”评级。SVB Leerink在6月13日(星期一)的一份报告中将Turning Point Treateutics的评级从“跑赢大盘”下调至“市场表现”,并将该公司的目标价从101.00美元下调至76美元。富国银行将Turning Point Treateutics的评级从增持下调至持平,并为该公司设定了76.00美元的目标价。在6月3日星期五的一份报告中。考恩在6月6日星期一的一份报告中将Turning Point Treateutics的评级从“跑赢大盘”下调至“市场表现”。最后,韦德布什在6月3日星期五的一份研究报告中将Turning Point治疗公司的评级从“跑赢大盘”下调至“中性”,并将该股的目标价从61.00美元上调至76.00美元。9名研究分析师对该股的评级为持有,3名分析师对该公司的评级为买入。根据MarketBeat.com的数据,该公司目前的共识评级为持有,共识目标价为78.22美元。
Insider Activity at Turning Point Therapeutics
转折点治疗公司的内部活动
Institutional Inflows and Outflows
机构资金流入和流出
Institutional investors and hedge funds have recently bought and sold shares of the company. Captrust Financial Advisors boosted its position in Turning Point Therapeutics by 176.5% in the first quarter. Captrust Financial Advisors now owns 1,045 shares of the company's stock worth $28,000 after purchasing an additional 667 shares during the last quarter. US Bancorp DE boosted its position in Turning Point Therapeutics by 139.6% in the first quarter. US Bancorp DE now owns 1,143 shares of the company's stock worth $31,000 after purchasing an additional 666 shares during the last quarter. Point72 Hong Kong Ltd purchased a new position in shares of Turning Point Therapeutics during the 1st quarter valued at about $96,000. PNC Financial Services Group Inc. lifted its position in shares of Turning Point Therapeutics by 11.6% during the 1st quarter. PNC Financial Services Group Inc. now owns 8,546 shares of the company's stock valued at $230,000 after buying an additional 888 shares in the last quarter. Finally, Virtu Financial LLC purchased a new position in shares of Turning Point Therapeutics during the 1st quarter valued at about $237,000. 90.33% of the stock is owned by hedge funds and other institutional investors.
机构投资者和对冲基金最近买卖了该公司的股票。CapTrust Financial Advisors在第一季度将其在Turning Point Treateutics的头寸提高了176.5%。CapTrust Financial Advisors在上个季度额外购买了667股后,现在拥有1,045股该公司股票,价值28,000美元。美国Bancorp DE在第一季度将其在Turning Point Treateutics的地位提高了139.6%。US Bancorp DE现在拥有1143股该公司股票,价值3.1万美元,此前在上个季度又购买了666股。Point72 Hong Kong Ltd在第一季度购买了Turning Point Treeutics的新股票头寸,价值约96,000美元。PNC金融服务集团在第一季度将其在Turning Point Treateutics的股票头寸提高了11.6%。PNC金融服务集团(PNC Financial Services Group Inc.)目前持有该公司8,546股股票,价值23万美元,上一季度又购买了888股。最后,Virtu Financial LLC在第一季度购买了Turning Point Treeutics的新头寸,价值约237,000美元。90.33%的股票由对冲基金和其他机构投资者持有。
Turning Point Therapeutics Company Profile
转折点治疗公司简介
(Get Rating)
(获取评级)
Turning Point Therapeutics, Inc, a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients.
Turning Point治疗公司是一家临床阶段的精确肿瘤学生物制药公司,致力于设计和开发针对癌症遗传驱动因素的治疗方法。它开发了一系列酪氨酸激酶抑制剂(TKI),针对TKI-NAI、̈Ve和TKI预治疗患者的癌症基因驱动因素。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on Turning Point Therapeutics (TPTX)
- Home Depot, Lowe's On Track To Grow 2022 Earnings
- Could Smaller be Better for Investors in Norwegian Cruise Lines?
- Walmart Or Target: Which Is The Stronger Stock?
- MarketBeat Podcast: Investing in What You Know Has Changed
- Can Etsy Continue to Thrive After the Pandemic?
- 免费获取StockNews.com关于转折点治疗(TPTX)的研究报告
- 家得宝,Lowe‘s有望在2022年实现收益增长
- 对挪威邮轮公司的投资者来说,更小的规模会更好吗?
- 沃尔玛和塔吉特:哪只股票更强?
- MarketBeat播客:投资你所知道的已经改变的东西
- 在大流行之后,Etsy能否继续蓬勃发展?
Receive News & Ratings for Turning Point Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turning Point Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
获得《转折点治疗日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Turning Point Treateutics和相关公司的最新新闻和分析师评级的每日简要摘要。